Nadège Kindt1, Jérôme R Lechien, Denis Nonclercq, Guy Laurent, Sven Saussez. 1. Laboratory of Anatomy and Cellular Biology, Faculty of Medicine and Pharmacy, Research Institute for Health Sciences and Technology, University of Mons (UMons), Pentagone 2A, 6 Ave du Champ de Mars, 7000, Mons, Belgium.
Abstract
PURPOSE: While macrophage migration inhibitory factor (MIF) has been extensively studied in the context of inflammation and inflammatory disorders, less work has been devoted to its involvement in cancer, notably in neoplastic progression. In a previous study, we have found evidence that MIF plays a role in head and neck squamous cell carcinomas (HNSCC). The current investigations were undertaken in order to estimate the importance of the MIF receptor, CD74 in the progression of HNSCC. METHODS AND RESULTS: In a cohort of 46 cases of oral cavity carcinomas, immunohistochemical staining revealed an increase in CD74 expression during progression from benign lesions to carcinoma. As shown by cell culture experiments using squamous carcinoma cell line (SCCVII) transduced with anti-CD74 shRNA, the amount of cell-produced VEGF was lower in SCCVII CD74KD cell line compared with control SCCVII CD74sc cell line, suggesting that CD74 could be implicated in angiogenesis in vivo. Furthermore, knockdown of CD74 decreased proliferation of SCCVII cells in vitro. The migration of SCCVII cells, as well as the cell secretion of matrix metallopeptidase 9, was also negatively affected by CD74 knockdown. These observations in vitro were confirmed in an orthotopic mouse model of SCC where tumors produced by SCCVII CD74KD cell inoculation were found to grow more slowly than tumors generated by SCCVII CD74sc cells. CONCLUSION: The clinical observations and experimental data reported here suggest that CD74, as well as MIF, plays a pivotal role in HNSCC progression.
PURPOSE: While macrophage migration inhibitory factor (MIF) has been extensively studied in the context of inflammation and inflammatory disorders, less work has been devoted to its involvement in cancer, notably in neoplastic progression. In a previous study, we have found evidence that MIF plays a role in head and neck squamous cell carcinomas (HNSCC). The current investigations were undertaken in order to estimate the importance of the MIF receptor, CD74 in the progression of HNSCC. METHODS AND RESULTS: In a cohort of 46 cases of oral cavity carcinomas, immunohistochemical staining revealed an increase in CD74 expression during progression from benign lesions to carcinoma. As shown by cell culture experiments using squamous carcinoma cell line (SCCVII) transduced with anti-CD74 shRNA, the amount of cell-produced VEGF was lower in SCCVII CD74KD cell line compared with control SCCVII CD74sc cell line, suggesting that CD74 could be implicated in angiogenesis in vivo. Furthermore, knockdown of CD74 decreased proliferation of SCCVII cells in vitro. The migration of SCCVII cells, as well as the cell secretion of matrix metallopeptidase 9, was also negatively affected by CD74 knockdown. These observations in vitro were confirmed in an orthotopic mouse model of SCC where tumors produced by SCCVII CD74KD cell inoculation were found to grow more slowly than tumors generated by SCCVII CD74sc cells. CONCLUSION: The clinical observations and experimental data reported here suggest that CD74, as well as MIF, plays a pivotal role in HNSCC progression.
Authors: H Lue; M Thiele; J Franz; E Dahl; S Speckgens; L Leng; G Fingerle-Rowson; R Bucala; B Lüscher; J Bernhagen Journal: Oncogene Date: 2007-02-19 Impact factor: 9.867
Authors: Cristiane M França; Aline C Batista; Ricardo C Borra; Jose A Ventiades-Flores; Elismauro F Mendonça; Alessandro M Deana; Raquel A Mesquita-Ferrari; Decio de Natali Caly; Sigmar de Mello Rode; Miriam R Faria Journal: J Oral Pathol Med Date: 2012-10-16 Impact factor: 4.253
Authors: Nadège Kindt; Julie Preillon; Herbert Kaltner; Hans-Joachim Gabius; Dominique Chevalier; Alexandra Rodriguez; Bryon D Johnson; Véronique Megalizzi; Christine Decaestecker; Guy Laurent; Sven Saussez Journal: J Cancer Res Clin Oncol Date: 2013-01-25 Impact factor: 4.553
Authors: Thorsten Hagemann; Stephen C Robinson; Richard G Thompson; Kellie Charles; Hagen Kulbe; Frances R Balkwill Journal: Mol Cancer Ther Date: 2007-07 Impact factor: 6.261